In summary, these data reveal that expression of the OX40 co-stimulatory molecule is controlled by a combined TCR/gc cytokine-dependent mechanism and that dual anti-OX40/IL-2 therapy was able to greatly augment tumor immunotherapy. The gene discussed is TNFRSF4; the disease is neoplasm.